ASP Isotopes issues letter to shareholders

ASP Isotopes released the following letter to stockholders from its Chairman and CEO, Paul Mann. “In light of the considerable progress made since my last shareholder letter approximately six months ago, and with our Annual Report on Form 10K for 2023 having just been filed, I wanted to personally communicate with you today to highlight some of our recent key milestones and discuss our future goals. Annual Report on Form 10-K was filed with 2023 annual results largely in line with expectations. Current balance sheet and available cash are at their strongest since the inception of the Company. The Company’s first commercial isotopes plant started processing raw materials for the anticipated production of enriched isotopes around mid-year. The Company signed a purchase agreement for the supply of highly enriched silicon-28, for use in next-generation semiconductors capable of enabling quantum computing and artificial intelligence. The Company signed a contract with a U.S.-based SMR company, pursuant to which the Company will engage in certain activities related to preliminary engineering design and planning for an enrichment facility for the production of nuclear fuels that are expected to be used in next-generation nuclear reactors. Construction underway of first quantum enrichment facility, focused on producing Ytterbium-176, an important feedstock used in the production of Lutetium 177 which is the active component of Novartis’ potential blockbuster for the treatment of prostate cancer Pluvicto. PET Labs FDG production grew 32% year on year in 2023 over 2022… Thank you for your interest and continued support.”